



(12) Translation of
European patent specification

(11) NO/EP 3016656 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/47 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/497 (2006.01)
A61K 31/506 (2006.01)
A61P 31/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.12.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.09.08
(86)	European Application Nr.	14758168.0
(86)	European Filing Date	2014.07.04
(87)	The European Application's Publication Date	2016.05.11
(30)	Priority	2013.07.05, US, 201361843155 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	ABIVAX, 5 rue de la Baume, 75008 Paris, Frankrike Centre National de la Recherche Scientifique (Etablissement Public), 3 rue Michel- Ange, 75794 Paris, Frankrike Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05, Frankrike UNIVERSITE DE MONTPELLIER, 163 rue Auguste Broussonnet, 34090 Montpellier, Frankrike
(72)	Inventor	TAZI, Jamal, 4 rue Condorcet, F-34380 Clapiers, Frankrike MAHUTEAU-BETZER, Florence, 36 avenue Hoche, F-78470 Saint Remy-les- Chevreuse, Frankrike NAJMAN, Romain, 29b rue du 11 novembre 1918, F-94240 L'Hay les Roses, Frankrike SCHERRER, Didier, 18 avenue de la Fée Mélusine, F-34170 Castelnau le Lez, Frankrike CAMPOS, Noëlie, Résidence Villa Borghese A3220 rue des Droits de l'Homme, F- 34920 Le Cres, Frankrike GARCEL, Aude, Le Palais Vinci D025 avenue Monteroni d'Arbia, F-34920 Le Cres, Frankrike

(74) Agent or Attorney RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES**

(56) References
Cited:

WO-A2-2010/143169

WO-A1-2014/055944

EP-A1- 2 465 502

EP-A1- 2 266 972

EP-A1- 2 757 161

Beatrice Macchi ET AL: "Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors", Viruses, vol. 3, no. 5, 5 May 2011 (2011-05-05), pages 469-483, XP055583869, DOI: 10.3390/v3050469


E. Balestrieri ET AL: "Effect of Lamivudine on Transmission of Human T-Cell Lymphotropic Virus Type 1 to Adult Peripheral Blood Mononuclear Cells In Vitro", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 9, 1 September 2002 (2002-09-01), pages 3080-3083, XP055583868, US ISSN: 0066-4804, DOI: 10.1128/AAC.46.9.3080-3083.2002

NADIA BAKKOUR ET AL: "Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 3, no. 10, 26 October 2007 (2007-10-26), pages 1530-1539, XP002629789, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.0030159

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse på formelen (Iq) til bruk i behandlingen av en retrovirusinfeksjon, der retrovirusinfeksjonen er forårsaket av et retrovirus valgt fra gruppen som består av humane leukemivirus HTLV-I, humane leukemivirus HTLV-II, apeleukemivirus eller STLV, og bovint leukemivirus eller BLV



der:

R uavhengig står for et hydrogenatom, en (C₁-C₃)alkoksygruppe eller en (C₁-C₃)fluoralkoksygruppe,

R' er et hydrogenatom eller en gruppe valgt blant en -NR₁R₂-gruppe, en N-metylpiperazinygruppe, en (C₁-C₃)alkoksygruppe og en morfolingruppe,

R₁ og R₂ uavhengig er et hydrogenatom eller en (C₁-C₃)alkylgruppe,

R'' er et hydrogenatom,

n er 1,

n' er 1,

og et farmasøytisk akseptabelt salt av dette.

2. Forbindelse ifølge krav 1 til bruk ifølge krav 1, der den minst ene forbindelsen er valgt fra gruppen som består av

- (143) 4-N,4-N-dimetyl-7-N-[4-(trifluormetoksy)fenyl]kinolin-4,7-diamin

- (144) 4-(morfolin-4-yl)-N-[4-(trifluormetoksy)fenyl]kinolin-7-amin

- (166) N-(4-metoksyfenyl)-4-(4-metylpiperazin-1-yl)kinolin-7-amin

- (167) 4-metoksy-N-[4-(trifluormetoksy)fenyl]kinolin-7-amin

- og et farmasøytisk akseptabelt salt av dette.